Protein arrays are described for screening of molecular markers and pathway targets in patient matched human tissue during disease progression. In contrast to previous protein arrays that immobilize the probe, our reverse phase protein array immobilizes the whole repertoire of patient proteins that represent the state of individual tissue cell populations undergoing disease transitions. A high degree of sensitivity, precision and linearity was achieved, making it possible to quantify the phosphorylated status of signal proteins in human tissue cell subpopulations. Using this novel protein microarray we have longitudinally analysed the state of pro-survival checkpoint proteins at the microscopic transition stage from patient matched histologically normal prostate epithelium to prostate intraepithelial neoplasia (PIN) and then to invasive prostate cancer. Cancer progression was associated with increased phosphorylation of Akt (P50.04), suppression of apoptosis pathways (P50.03), as well as decreased phosphorylation of ERK (P50.01). At the transition from histologically normal epithelium to PIN we observed a statistically signi®cant surge in phosphorylated Akt (P50.03) and a concomitant
Introduction
The activated (e.g. phosphorylated) state of signal pathway checkpoints in vivo can not be ascertained from gene expression alone (Williams and Hochstrasser, 1997) . Nevertheless, the state of such pathways may be a key determinant of diseased cellular physiology such as early stage cancer. In glandular tissue such as breast and prostate, malignant neoplasia originates in microscopic lesions, which evolve over time. Stationary¯at epithelium and myoepithelium, is replaced by the piling up of multiple layers of neoplastic cells within the duct or gland lumen. As time proceeds, there is a transition to invasive carcinoma. The hallmark of invasion is disruption of the periglandular basement membrane, and the migration of neoplastic cells into the surrounding stroma. It is now understood that premalignant progression taking place in such microscopic lesions may be the outward manifestation of a complex tissue microenvironment, in which positive and negative interactions are taking place between organ parenchymal cells, stroma, blood vessels, and the extracellular matrix (Hanahan and Weinberg, 2000) . At any point in time the summation of these interactions is re¯ected in the activation of signal transduction networks in the tissue cells. Cell culture systems, and even animal carcinogenesis models, may not accurately represent the complexity and the true physiologic state of the diseased human tissue (Page et al., 2000; Ornstein et al., 2000) . Consequently we sought to develop a new means to analyse the state of critical signaling proteins within the individual cell types comprising the evolving premalignant lesion in human tissue.
Immunohistochemistry can provide clues to the abundance of cellular protein antigens in tissue. However, immunohistochemistry is not suitable for the analysis of subtle quantitative changes in multiple classes of proteins taking place simultaneously within an individual cell type. Such subtle changes may make all the dierence in the slow progression of precancerous lesions over many years. In particular, changes in the activation status of signal pathway circuits that regulate downstream cell cycle progression and prosurvival can generate an imbalance, which ultimately results in the loss of cell growth control and the net accumulation of neoplastic cells. Small reductions in the apoptotic rate, which normally balances cell death against the cell population birth rate, will cause cell population growth. Growth is further stimulated if progression through the cell cycle is perpetuated rather than being checked as it might be during dierentiation. We therefore set out to develop a highly quantitative and precise protein array technology that could ascertain the changing state of protein circuitry regulating growth and survival in microscopic premalignant lesions and invasive carcinoma from human tissue specimens.
Protein microarrays are now being designed to investigate large study sets of protein interactions in parallel similar to gene expression arrays recently used in functional genomics (Emili and Cagney, 2000; Fodor et al., 1991; Kononen et al., 1998; MacBeath et al., 1999; Ge, 2000; Englert et al., 1999; Lueking et al., 1999; Arenkov et al., 2000; Ekins and Chu et al., 1991; Rowe et al., 1999; Jones et al., 1998; Buckholtz et al., 1999) . However, in contrast to previous antibody-, ligand-, or heterogeneous tissue fragment arrays, which mostly incorporate the use of single probes, our reverse phase protein array immobilizes whole protein lysates from histopathologically relevant cell populations procured by Laser Capture Microdissection. The array is designed to capture various stages of microscopic progressing cancer lesions within individual patients. Furthermore, each patient set is arrayed in miniature dilution curves to facilitate accurate quanti®cation and enlarge the dynamic range. In contrast to previous antibody arrays, ligand arrays, or heterogeneous tissue fragment arrays, our protein array contains immobilized proteins from pure microdissected human tissue cells.
We have applied this microarray to analyse, in human tissue, the state of checkpoints for pro-survival and growth regulation at the transition from histologically normal epithelium, to Prostate Intraepithelial Neoplasia (PIN) and into prostate carcinoma at the invasion front.
Results
Precision, specificity and dynamic range of reverse phase protein arrays
Reverse phase protein microarrays combine laser capture microdissection (LCM) (Emmert-Buck et al., 1996) and cDNA microarray technologies (Schena et al., 1995; De Risi et al., 1996; Lipshutz et al., 1999) . First, histophathological relevant cell populations are microdissected, lysed in a suitable lysing buer, and approximately 3 nL of that lysate are arrayed with a pin based microarrayer onto glass backed nitrocellulose slides at de®ned positions. These applications result in 250 ± 350 mm wide spots each containing the whole cellular repertoire corresponding to a given pathologic state that has been captured. Subsequently, each slide can be probed with an antibody that can be detected by¯uorescent, colorimetric, or chemiluminescent assays (Figure 1 ). Over 1000 individual cellular lysates can be accommodated on a 20630 mm slide with 1 m1 of lysate.
We tested the precision and linearity of our platform using microarrayed dilution curves or recombinant prostatic speci®c antigen (PSA). Twenty standard curves of 20 fg to 1.25 fg were arrayed on each slide. This experiment was carried out between seven dierent slides providing ultimately 140 data points for analysis. Intra spot reproducibility was measured by taking the mean intensity of 20 individual applications for a given concentration within a slide and comparing it to the mean intensity of the remaining six slides. Two representative chromogen stained arrays of this experiment are shown in Figure  2a . Incubating the array with IgG isotype matched mouse control antibody and secondary antibody alone as negative controls yielded no detectable signal (data not shown). Linear correlations were observed for individual rows on each array with r 2 values ranging from 0.999 to 0.990 ( Figure 2c ). Analysis of inter and intra spot reproducibility and linearity showed good correlation over the examined curve with a correlation coecient r 2 of 0.973 ( Figure 2d ). The detection limit (de®ned as two standard deviations above background) was found to be at least 10 721 mol for recombinant PSA, while the`functional sensitivity' de®ned as the lowest concentration measured with a CV% of 20% within an array was determined to be 5610 720 mol. Nevertheless, the sensitivity of individual antibody antigen interactions for any given detection system are highly dependent on the relative abundance of the antigen antibody species and the binding anities between the probe antibodies and the immobilized antigens (Haab et al., 2000) .
To test whether microdissected lysates can be applied on our array format, we arrayed triplicate dilution curves from LCM procured esophageal normal epithelial cell lysates ranging from 120610 74 to 4610 74 cell equivalencies per array spot on seven slides. Arrays were probed against annexin-1 ( Figure  3a ). Good linearity and reproducibility from sample to sample with r 2 of 0.952 was shown for the whole dataset analysed (Figure 3b ). The coecient of variance for inter and intra spot reproducibility ranges from 1.66 and 1.25% at high cellular concentration to 21.18 and 39.4% (intra and inter spot reproducibility, respectively) at the limit of detection (Figure 3c ). Negative control slides yielded no detectable signal. These results reveal that the micro application of recombinant and microdissected protein lysates onto nitrocellulose slides can be applied reproducibly and quanti®able.
Candidate validation in human tissue
We recently reported that annexin-1 protein expression in squamous esophageal and prostate cancer is signi®cantly less than that found in adjacent normal epithelium (Emmert-Buck et al., 2000; Paweletz et al., 2000) . A prospective study showed that the histologic progression of clinically detectable precursor lesions to esophageal cancer, i.e., mild, moderate and severe dysplasia, is associated with an increased invasive risk of developing invasive disease. To validate whether annexin-1 might serve as an early diagnostic marker we arrayed 10 dierent patient matched normal (N), low (L) and high grade (H) dysplasia, and invasive esophageal carcinoma (T) cell populations on one array from fully embedded esophageal resections. Slides in Figure 4a were probed against: (a) annexin-1 and to normalize protein loading; (b) actin. When identical arrayed slides were incubated with normal rabbit serum or secondary antibody alone no interaction was detected (data not shown). The adjusted expression protein level for each foci (n=40) was determined by dividing the median level of annexin-1 expression by the median level of actin expression. The mean adjusted annexin-1 expression for each histologic category decreased with increasing disease severity (N mean (standard error SE) 0.995 units (0.055), LG 0.707 (0.080), HG 0.611 (0.080), and CA 0.565 (0.045)) Figure 1 Schematic overview of longitudinal cancer progression investigation by cell captured lysate arraying. De®ned patient matched cell populations are microdissected, lysed, and immobilized onto nitrocellulose slides at distinct positions. Each patient set is designed so that it contains its longitudinal cancer progression vertically, and corresponding dilution curves to each disease state horizontally. After arraying these slides are incubated with an antibody that can be detected by chemiluminescencent,¯orescencent, or colorimetric assays. Intensity of the signal is proportional to the concentration of the target protein ( Figure 4b ). Each disease category had signi®cantly less protein expression of annexin-1 than normal epithelium (P50.02) for all comparisons. Speci®city of antibodies was con®rmed by Western blot analyses from the same cases (Figure 4c ). These ®nding indicate: (a) that the reduction of annexin-1 protein is an early event in the pathogenesis of squamous esophageal cancer and appears to progressively decrease as the risk of developing invasive cancer increases; and (b) that the reverse phase array is a viable approach to the analysis of multiplexed proteomic outcomes.
Pro-survival and cell proliferation stimuli in prostate cancer progression.
It has been suspected that the Akt regulated pro-survival pathway and the mitogen kinase activated cell proliferation pathway may be disregulated during progression Implementation of reverse phase microarrays in the study of tumor progression CP Paweletz et al from normal to invasive cancer (Gra et al., 2000; Zimmermann and Moelling, 1999; Dimmeler and Zeiher, 2000; Franke et al., 1997; York et al., 1998) . However this has not been previously studied in the context of longitudinal (i.e. patient matched normal, PIN, and invasive carcinoma) progression in the most biological relevant human tissue study sets. We analysed phosphorylated ERK, phosphorylated Akt, and cleaved PARP and Caspase 7 protein levels in patient matched normal (N), PIN (P), invasive carcinoma (T), and stroma (S) cell populations (Figure 5a ± c) . We found that in 10 out of 10 longitudinal cases phosphorylated ERK protein levels (normalized to total ERK) are suppressed during the evolution of progression (P50.01) with normal epithelium expressing highest level of phosphorylated ERK followed by a gradual decline with disease progression (Figure 5e ). Total ERK levels were ubiquitously expressed with no detectable change in protein status per disease progression across all cases. Phosphorylated Akt levels concomitantly increased (P50.03) between normal and PIN, and between normal and invasive cancer (P50.04) (Figure 5e ). Subsequent study on cleaved PARP and cleaved Caspase 7 for these cases showed a direct relationship with increased activated Akt levels and decreased apoptosis between normal epithelium and PIN (P50.03), and between normal and tumor (P50.05). The highest change between activated Akt and subsequently cleaved Caspase 7 and PARP were observed between the neoplastic transition of normal to PIN. Speci®city of these results was validated by micro Western analyses from microdissected relevant cell populations from the same cases for each antibody (Figure 5d ). Subsequent studies by Western analyses from the same cases on the apoptosis pathway directly aected by Akt showed suppression of downstream apoptosis pathways through phosphorylation of glycogen syntase kinase-3 (GSK3-b) and cleaved caspase 7 (Figure 5d ).
Discussion
Histopathologically, PIN represents the closest precursor lesion of prostatic tumorigenesis (Botswick, 1995) . High grade PIN is characterized by speci®c nuclear and morphologic features, such as enlargement of nuclei and partial breakage of the basal membrane. Koch et al. and others have proposed that regulation of apoptosis and proliferation could lead to cell accumulation in PIN (Koch et al., 2000; Xie et al., 2000; Krajewaska et al., 1996) . However, previous studies were based on immunohistochemistry and TUNEL assays applied to rat and human prostate tissue.
In the present study we now provide direct quantitative evidence that suppression of apoptosis in Akt, and cleaved Caspase 7 and cleaved PARP levels. Cancer progression was associated with increased phosphorylation of Akt (P50.03 and P50.04 for neoplastic transition from N to P and N to T, respectively), suppression of apoptosis pathways (P50.03 and P50.05, N to P and N to T, respectively), as well as decreased phosphorylation of ERK (P50.01 for all comparisons). All statistical comparisons were carried out using the Wilcoxon rank-sum test. (f) Immunohistochemistry staining for two cases for phospho ERK con®rming result obtained by Western blot analysis and reverse phase microarray PIN and invasive prostate cancer may be associated with phosphorylation of Akt and subsequent inactivation of its substrate GSK3-b. Akt has been shown to phosphorylate and inactivate GSK3-b/a both in vitro and in vivo (Cross et al., 1995) . Subsequent studies on GSK3-b demonstrated that transfection of constitutively activated GSK3-b in Rat1 and PC 12 cell lines induces apoptosis, while overexpression of dominant negative mutant GSK3-b blocks apoptosis (Pap and Cooper, 1998) . This suggests that cell survival through GSK-3 activity can be regulated by growth factors through the phosphatidyl-inositol 3-kinase-Akt pathway. Moreover we verify that downstream components of the apoptotic cascade (cleaved and non cleaved 7, as well as cleaved and non cleaved PARP) are also shifted toward pro-survival. This data is in keeping with known pro-survival pathways, which emanate from Akt through its substrates (Pap and Cooper, 1998; Yao and Cooper, 1995) .
These results demonstrate a highly signi®cant reduction in the ratio of phosphorylated ERK to total ERK during the longitudinal progression of human prostate cancer. High grade PIN exhibited a lower level of phospho-ERK compared to normal appearing epithelium. Invading carcinoma cells (average Gleason grade 6.6) contained phospho-ERK levels that were even further reduced compared to PIN. We con®rmed this quantitative dierence in phosphorylated ERK using immunohistochemistry on the same cases. Gioeli et al. (1999) conducted an immunohistochemistry study of prostate tumor tissue and reported low staining of phospho-ERK in tumors with a Gleason score of less than 7. The loss of sustained phospho-ERK during progression is in keeping with the antiproliferative eects of sustained ERK activity in cultured cells (Marshall, 1995; York et al., 1998; Frey and Mulder, 1997) . Thus, during the transition to invasive carcinoma, suppression of sustained phosphorylation of ERK, known to cause a cell cycle block, may enable cellular proliferation.
These ®ndings support a general hypothetical model of prostate cancer progression. Augmentation of the ratio of phosphorylated Akt to total Akt will suppress downstream apoptosis pathways through intermediate substrates such as GSK3-b. Reduction in apoptosis will shift the balance of cell birth and death rates favoring accumulation of cells within the prostate gland. Piling up of cells within the gland is a major pathologic hallmark of PIN. Pro-survival is required for migrating cells to resist the pro-apoptotic signals which take place during the disruption of integrin mediated adhesion to extracellular matrix molecules. In parallel, transient ERK activation, and augmentation of pro-survival pathways may be associated with cellular migration. Activation of Akt, a substrate of P13K, can therefore promote cell motility and survival as the invading cancer cells leave the gland and invade the stroma.
In conclusion, a novel protein array technology was developed and applied to gain previously unknown insights about speci®c molecular events taking place in microscopic disease progression within individual patients. This technology is broadly applicable to high-throughput molecular analysis of proteomic changes in tissue cells during development or disease, or after treatment. Genomic and proteomic initiatives are yielding growing catalogs of molecules which may be disease related, and thereby constitute candidates for diagnostic or therapeutic targets: (a) Is the candidate molecule actually present or altered in the human disease lesion?; (b) Does this alteration transcend patient anecdote to a molecular phenotype altered in a majority of patients; and (c) Is the candidate protein within a relevant pathway that can be veri®ed to be aberrant in the diseased tissue chosen for treatment? The use of reverse phase microarrays may speci®cally target these questions.
Materials and methods

Materials
Fully embedded esophageal specimens (n=40) were obtained from patients who presented to the Shanxi Cancer Hospital in Taiyuan, People's Republic of China. These foci were longitudinally arrayed into ten cases comprising of normal, low and high-grade dysplasia, as well as invasive carcinoma from the same patient. Fourfold dilution curves of the each lysate were arrayed directly underneath each sample to ensure proper dynamic ranges for all antibodies tested. The Institutional Review Board (IRB) of the Shanxi Cancer Hospital and the US National Cancer Institute approved this study. Radical prostatectomy samples (n=40) were from men that presented with localized prostate cancer. Whole mounted sections were used for immunoblotting, immunohistochemistry and microdissection. Longitudinally matched foci were arrayed into 10 cases comprising of histologically normal epithelium, PIN, invasive cancer, and corresponding stroma cell population. Samples were ®xed in 70% ethanol and completely embedded in paran. All specimens were studied anony-mously under a NIH IRB Waiver.
Microdissection and cellular lysate arraying
Microdissection was carried out under careful direct pathological examination as previously described using a Pixcell 200 Laser Capture Microdissection system (Arcturus Engineering, Mountain View, CA, USA). Brie¯y, prior to microdissection paran embedded tissue sections were deparanized by completely submersing the slide in Xylene three times for 6 min each and furthermore stained with a modi®ed H&E staining protocol. The staining protocol calls for treatment of tissue sections sequentially in 100, 95, 70% ethanol, HPLC grade water, hematoxylin (Sigma, St. Louis, MO, USA), HPLC grade water, blueing solution (Sigma, St. Louis, MO, USA), 70, 95, 100% ethanol for 20 s each and ®nal dehydration in Xylene. All staining baths contain 10 mmol Complete TM (Boehringer Mannheim, Germany) protease inhibitors. Between 500 and 3000 LCM shots (approximately 2500 and 15 000 cells, respectively) were acquired per investigated foci. For phosphorylated signaling molecules 3000 LCM pulses are the absolute minimum that needs to be microdissected. Microdissected cells were lysed in 30 ml of lysing buer containing 1 : 1 mixture of 26SDS electrophoresis buer (125 mM Tris pH 6.8, 4% SDS, 10% glycerol, 2% b-mercaptoethanol) and Tissue Protein Extraction Reagent (TPER, Pierce, Rockford, IL, USA) for 2 h at 708C. After cell lysis samples were boiled beween 3 and 5 min each and 3 nl of the lysate were arrayed with a pin and ring GMSE 470 microarrayer (Aymetrix) using a 375 micron pin onto nitrocellulose slides with a glass backing (Schleicher and Schuell, Keene, NH, USA). Spatial densities of 980 spots/ slide and greater can easily be accommodated on a 20 630 mm slide.
Staining was carried out on an automated slide stainer (Dako, Carpinteria, CA, USA) using the catalysed signal ampli®cation system per manufacturer's recommendation (Dako, Carpinteria, CA, USA). Brie¯y, after micro application of cellular lysates the slides were treated for 15 min with Reblot TM (Chemicon, Temecula, CA, USA) and subsequently washed three times for 10 min each with TBS washing buer (300 mmol NaC1, 0.1% Tween 20, 50 mmol Tris, pH 7.6). After treatment the arrays were blocked in a 0.5% casein solution for 30 min under constant rocking. Between each following step arrayed slides were washed three times 5 min each with TBS washing buer. Endogenous biotin was blocked using the biotin blocking kit (Dako, Carpinteria, CA, USA) for 5 min, followed by application of protein block (Dako, Carpinteria, CA, USA) for 5 min, primary antibody diluted in antibody diluent (Dako, Carpinteria, CA, USA) at a concentration of 1 : 1000 for 30 min and ®nally secondary link antibody (Dako, Carpinteria, CA, USA) at a concentration of 1 : 100 for anti-mouse (diluted in antibody diluent) and neat for anti-rabbit for 30 min.
Ampli®cation and staining was carried out as follows: The subsequent labeled microarray was treated with a streptaviding-biotin complex (Dako, Carpinteria, CA, USA) solution for 15 min, ampli®cation reagent (biotinyl tyramide and hydrogen peroxidase) for 15 min, streptaviding-peroxidase for 15 min, and ®nally stained using 3,3'-diaminobenzidine tetrahydrochloride as chromogen. Excessive studies using a variety of staining methods (including chemiluminescent detection) showed this method to be superior with regard of sensitivity and signal to noise ratio. If chemiluminescent detection readout is desired arrayed nitrocellulose slides can be treated according to the protocol described for micro immunoblotting.
Speci®city of each antibody was tested by Western blot. Antibodies were used at following concentrations: Rabbit antiannexin-1 1 : 2500 (Zymed Laboratories, San Francisco, CA, USA), mouse anti-actin 1 : 4000 (Calbiochem, San Diego, CA, USA), mouse anti-PSA 1 : 4000 (Scripps Laboratories, San Diego, CA, USA), rabbit anti-Akt 1 : 500 (Cell Signaling, Beverly, MA, USA), rabbit anti-phosphoAkt 1 : 500 (Cell Signaling, Beverly, MA, USA), mouse anti-ERK 1 : 1000 (Transduction Laboratories, San Diego, CA, USA), rabbit anti-phosphoERK1/21 : 1000 (Cell Signaling, Beverly, MA, USA), rabbit anti cleaved-PARP and anti cleaved-caspase 7 1 : 500 (Cell Signaling, Beverly, MA, USA). Negative controls were carried out at following concentrations: isotype matched IgG mouse 1 : 1000 (Sigma, St. Louis, MO, USA), anti-mouse 1 : 100 (Dako, Carpinteria, CA, USA), anti rabbit neat (Dako, Carpinteria, CA, USA). Anti-phospho ERK (Cell Signaling, Beverly, MA, USA) recognizes phosphorylated threonine 202 and tyrosine 204 of p44 and p42. Speci®city was con®rmed by Western blot analysis.
Image and statistics analyses
Stained slides were scanned on a UMAX scanner with Adobe PhotoShop 5.5 at a resolution of 600 dpi for analyses. Scanned images (saved as tif. ®le) were analysed with Image Quant (Molecular Dynamics, Sunnyvale, CA, USA) using thè histogram' option as background correction of choice. The Wilcoxon rank-sum test was used to test group dierences in the adjusted mean protein expression between histologically normal epithelium, PIN, stroma, and invasive lesions. Two sided statistical tests are used throughout; P-values50.05 were considered to be statistically signi®cant. All analyses were performed using the statistical software package STATA (STATA Corporation, College Station, TX, USA). Linear regression analysis and graphing were performed by Origin 4.1.
Immunoblotting
All antibodies were used at a concentration of 1 : 1000. Rabbit anti-annexin-1 (Zymed Laboratories, San Francisco, CA, USA), mouse anti-actin (Calbiochem, San Diego, CA, USA), (Scripps Laboratories, San Diego, CA, USA), rabbit anti-Akt (Cell Signaling, Beverly, MA, USA), rabbit antiphosphoAkt (Cell Signaling, Beverly, MA, USA), mouse anti ERK (Transduction Laboratories, San Diego, CA, USA), rabbit anti-phosphoERK (Cell Signaling, Beverly, MA, USA), rabbit anti cleaved-PARP and anti cleaved-caspase 7 (Cell Signaling, Beverly, MA, USA), GSK3-b (Cell Signaling, Beverly, MA, USA), anti caspase 7 and anti PARP (Cell Signaling, Beverly, MA, USA). Western blotting was performed for 2 h using a BioRad SemiDry apparatus with Immobilon-P PVDF membrane (Millipore, Bedford, MA, USA) at a constant voltage of 25 V and 10A/10 cm 2 . Chemiluminescent detection was carried out using CDP Star TM (Tropix, Bedford, MA, USA) per recommendations of the manufacture. Brie¯y, membranes were blocked in Iblock supplemented with 0.01% v/v Tween 20 for 45 min and incubated with a primary antibody diluted in blocking buer at a concentration of 1 : 1000 for 2 h. Membranes were washed three times for 5 min with blocking buer after which the corresponding secondary antibody (1 : 5000) was incubated for 30 min. The blot was subsequently washed three times for 5 min with blocking buer, rinsed twice with 16 assay buer and developed with CDP Star substrate supplemented with 1 : 20 dilution of Nitro Block II until bands were clearly visible.
